A Case of Primary Pulmonary Plasmacytoma Presenting as Endobronchial Mass.
10.4046/trd.2004.56.6.664
- Author:
Soon Yong SUH
1
;
Gang Jee KO
;
Chung Ho KIM
;
Youn Ho KIM
;
Sung Yong LEE
;
Sang Yeub LEE
;
Je Hyeong KIM
;
Chol SHIN
;
Jae Jeong SHIM
;
Kwang Ho IN
;
Kyung Ho KANG
;
Se Hwa YOO
Author Information
1. Department of Internal Medicine, College of Medicine Korea University, SEOUL, KOREA. pulsy0309@hotmail.com
- Publication Type:Case Report
- Keywords:
pulmonary plasmacytoma;
extramedullary plasmacytoma;
endobronchial mass
- MeSH:
Dexamethasone;
Drug Therapy;
Gastrointestinal Tract;
Humans;
Lung;
Melphalan;
Middle Aged;
Multiple Myeloma;
Neoplasms, Plasma Cell;
Plasmacytoma*;
Pleural Effusion;
Prednisolone;
Radiotherapy;
Recurrence;
Thalidomide
- From:Tuberculosis and Respiratory Diseases
2004;56(6):664-669
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Extramedullary plasmacytoma(EMP) comprises 5% of all plasma cell neoplasms and commonly occurs in the upper airway or digestive tract. However, it rarely develops in the lungs. We present a case of primary pulmonary plasmacyotma in a 45 year old man, who presented as an endobronchial mass with a pleural effusion, but without evidence of multiple myeloma. The treatment options for EMP include surgery, surgery and radiotherapy, surgery and chemotherapy or chemotherapy alone. Surgery and radiation therapy appeared to be equally effective forms of treatment. The local recurrence rate was reported to be 30%, with 48% progressing to multiple myeloma, and median survival was reported to be 63-101 months. Our patient was initially treated with melphalan and prednisolone. However the disease progressed, and radiotherapy was combined with chemotherapy. In addition, the chemotherapy regimen was also changed to thalidomide and dexamethasone. The patient did not respond to this treatment regimen and finally died.
